GelMEDIX Completes $13 Million Seed Financing and Announces First Partnership

— Proceeds to support advancement of lead cell therapy program for Geographic Atrophy and next-generation hydrogel regenerative therapy platform —

— Partnership with global pharmaceutical company will leverage GelMEDIX regenerative medicine technology to develop stem cell-derived cell therapies —

CAMBRIDGE, Mass., Feb. 17, 2026 /PRNewswire/ — GelMEDIX, Inc., a biotechnology company developing regenerative therapies to restore vision, announced today the completion of a $13 million seed financing led by Safar Partners, with participation from HTL Biotechnology, Beacon Angels, TiE Boston Angels, Boston Harbor Angels, and other investors. GelMEDIX will apply the proceeds to advance the company’s lead program, GMX-101, a retinal pigment epithelial (RPE) cell therapy to treat late-stage Geographic Atrophy (GA). GA is a progressive, advanced form of dry age-related macular degeneration (dAMD) that causes permanent, irreversible central vision loss. The financing will also support the continued development and validation of GelMEDIX’s proprietary injectable hydrogel scaffold platform, which is engineered to optimize the delivery, efficacy, and safety of cell and gene therapies. Michael J. Cima, PhD, David H. Koch Professor of Engineering at the Massachusetts Institute of Technology, and Parinaz Motamedy, MBA, Partner, Safar Partners, were appointed to the GelMEDIX Board of Directors in connection with the financing. Read More>>